A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT06817356
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Mazdutide — DRUGAdministered SC
- Placebo — DRUGAdministered SC
Study Details
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Key Dates
- Start date
- Feb 6, 2025
- Status verified
- Mar 2026
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: MazdutideMazdutide administered subcutaneously (SC).
- Placebo Comparator: PlaceboPlacebo administered SC.
Primary Outcome Measure
Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method [ Time Frame: Baseline, Week 28 ]
Locations (25)
Find similar trials in Scottsdale, AZ
By condition
By specialty
By research site
Related Studies
- Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSDPHASE2 · Recruiting · NYU Langone Health · New York, New York
- The Role of Brief Potent Glutamatergic Modulation in Addressing Problem DrinkingPHASE2 · Recruiting · New York State Psychiatric Institute · New York, New York
- Local Participatory Systems Dynamics to Increase Reach of Evidence Based Addiction and Mental Health CareEnrolling By Invitation · Palo Alto Veterans Institute for Research · Palo Alto, California
- Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol TreatmentRecruiting · Butler Hospital · Providence, Rhode Island